Pinatuzumab is a humanised monoclonal antibody targeting CD22, commonly used to synthesise the ADC molecule Pinatuzumab vedotin, which is employed in the study of B-cell malignancies such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL).
Reinheit:
95.00%
CAS Nummer:
[1639820-81-7]
Target-Kategorie:
Integrin|||Immunology/Inflammation related
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten